Kymera Director Granted $744K Stock Options Package with One-Year Vest

Form 4 Filing Details: Director John Maraganore of Kymera Therapeutics (KYMR) received a stock option grant on June 25, 2025, representing a significant insider transaction.

Rhea-AI Filing Summary

Form 4 Filing Details: Director John Maraganore of Kymera Therapeutics (KYMR) received a stock option grant on June 25, 2025, representing a significant insider transaction.

Key Transaction Details:

• Acquired 16,000 stock options with exercise price of $46.47 per share
• Options expire on June 24, 2035
• Vesting occurs at earlier of June 25, 2026 or next annual stockholder meeting
• Transaction reported as direct ownership

This grant appears to be part of the company's director compensation program. The options provide Maraganore with the right to purchase KYMR shares at the specified strike price, aligning his interests with shareholders through potential stock price appreciation over the next decade.

Insider Trade Summary

Grant/Award: 16,000 shares

Grant/Award 1 txn

Insider MARAGANORE JOHN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 16,000 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 25, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did KYMR director John Maraganore receive on June 25, 2025?

John Maraganore received 16,000 stock options with an exercise price of $46.47. These options are rights to buy KYMR common stock and will expire on June 24, 2035.

When do John Maraganore's KYMR stock options vest?

The 16,000 stock options will vest in full upon the earlier of: (i) June 25, 2026 or (ii) the date of the next annual meeting of Kymera Therapeutics' stockholders.

What position does John Maraganore hold at KYMR?

According to the Form 4 filing, John Maraganore serves as a Director of Kymera Therapeutics, Inc. (KYMR). The filing indicates he is not an officer or 10% owner of the company.

What was the total value of stock options granted to KYMR director Maraganore?

The Form 4 shows that John Maraganore received 16,000 stock options at an exercise price of $46.47 per share. The options were granted at $0 cost to Maraganore, as they are part of director compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2025 - 09:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MARAGANORE JOHN

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$46.47	06/25/2025		A		16,000		(1)	06/24/2035	Common Stock	16,000	$0	16,000	D

Explanation of Responses:

1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 25, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders.

	/s/ Bruce Jacobs, as Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.